T2Hemostasis provides reliable and rapid results when compared to conventional systems

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the presentation of new data on hemostasis monitoring at the American Association for Clinical Chemistry Annual Meeting, July 15-19, 2012, in Los Angeles, CA. T2Hemostasis is the first platform capable of rapidly characterizing key coagulation, platelet and other hematologic factors directly from whole blood on a single, compact instrument. The data presented at AACC demonstrate that T2Hemostasis provides reliable and rapid results when compared to conventional systems.   

"T2Hemostasis, which utilizes the company's proprietary T2MR detector, is able to monitor several key hemostasis measurements, including clotting time, platelet activity, fibrinolysis and hematocrit, on a single assay in minutes," said John McDonough, CEO, T2 Biosystems. "T2 Bio's approach could enable more effective decisions for anticoagulation and anti-platelet therapies, as well as the selection of appropriate transfusion products during cardiovascular procedures. The benefits of improved hemostasis monitoring and therapeutic decision-making have a tremendous potential impact on the cost and quality of healthcare."

The presentation entitled "Characterization of new real-time hemostasis monitoring device for multiplexed detection of PT/INR, platelet activity, fibrinolysis, and hematocrit" was authored by T.J. Lowery, V. Papkov, E.C. Thayer, C. Rittershaus and V. Demas. The T2Hemostasis assay was used to demonstrate correlations with established methods for measuring PT/INR (n>40, R2>0.9), clotting time (n>20, R2>0.8), platelet activity (n>12, R2>0.9), fibrinolysis>2>0.75) and hematocrit (n>20, R2>0.9) using human plasma and blood samples. Additionally, rapid and direct measurement of effectiveness of anti-platelet drugs, such as Aspirin and Abciximab, was reported. T2Hemostasis provides rapid, real-time multiplexed monitoring with small sample volumes (<40 µL) of blood or plasma, down to a fingerstick test on a low cost and compact device.


T2 Biosystems    


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
You might also like... ×
New research could lead to 'breakthrough' for myelodysplastic syndrome